- Center on Health Equity and Access
- Clinical
- Health Care Cost
- Health Care Delivery
- Insurance
- Policy
- Technology
- Value-Based Care
Sue Friedman on Targeted Therapies and Knowing Family History of Cancer
Genetic testing and understanding family history of cancer is important because more and more targeted therapies are coming out that are designed to work with specific mutations or inherited forms of mutations, said Sue Friedman, DVM, executive director of FORCE: Facing Our Risk of Cancer Empowered.
Genetic testing and understanding family history of cancer is important because more and more targeted therapies are coming out that are designed to work with specific mutations or inherited forms of mutations, said Sue Friedman, DVM, executive director of FORCE: Facing Our Risk of Cancer Empowered.
Transcript
Why is it important for people to know more about genetic testing, especially those with a family history of cancer?
There are a lot of reasons why it’s important to know this information, and one of the things that’s been exciting that’s coming out of this [2019 American Society of Clinical Oncology Annual Meeting], but also other conferences over the years, have been these new agents, known as PARP [poly (ADP-ribose) polymerase] inhibitors, that are really targeted therapies and they were designed specifically with BRCA mutations, although now they’re looking at how they work in other mutations, as well.
And, so right now, these agents are approved for people with mutations and in some cases without mutations, for ovarian cancer, metastatic breast cancer. We’re really excited because there’s some data presented here about treated in pancreatic cancer in patients with inherited mutations. These studies are particularly exciting to FORCE, because we were part of the efforts to recruit patients and accrue for these clinical trials. So, watching the data mature and be presented and watching that they’re every promising and hopeful is very exciting to us and it allows us to go back to the community and share that hopeful information with them.
Overcoming Employment Barriers for Lasting Social Impact: Freedom House 2.0 and Pathways to Work
April 16th 2024To help celebrate and recognize National Minority Health Month, we are bringing you a special month-long podcast series with our Strategic Alliance Partner, UPMC Health Plan. Welcome to our second episode, in which we learn all about Freedom House 2.0 and the Pathways to Work program.
Listen
Dr Michael Farwell on FDG PET/CT Imaging to Predict Immunotherapy Response in Advanced Melanoma
April 15th 2024Michael Farwell, MD, associate professor of radiology at the Hospital of the University of Pennsylvania, provides insights into a study on the benefits of using 18F-fluorodeoxyglucose (FDG) PET/CT imaging to detect metabolic tumor changes in skin cancer.
Read More
Making Giant Strides in Maternity Health Through Baby Steps
April 9th 2024To help celebrate and recognize National Minority Health Month, we are kicking off a special month-long podcast series with our strategic alliance partner, UPMC Health Plan. Welcome to our first episode, which is all about the Baby Steps Maternity Program and its mission to support women throughout every step of their pregnancy journey.
Listen
Increasing Lp(a) Awareness for Better Cardiovascular Health: Dr Mary McGowan
March 24th 2024For Lp(a) Awareness Day, Mary McGowan, MD, FNLA, chief medical officer of the Family Heart Foundation, highlights how most people with elevated Lp(a) are completely unaware that they have this increased risk and calls for increased testing.
Read More
Dr Al Benson on Reimbursement for Supportive Care When Treating Patients With Cancer
March 22nd 2024Al Benson, MD, FACP, FACCC, FASCO, medical oncologist at Northwestern University Feinberg School of Medicine and associate director of the Robert E. Tillery Comprehensive Cancer Center, discussed findings from a national survey assessing barriers to comprehensive cancer care delivery.
Read More
